Collectively, these data suggest that BCI and BCI‐215 have toxic activities unrelated to their DUSP1/6 enzyme targets in several NB cell lines and thus cannot be recommended as reliable DUSP1/6 inhibitors in this context. The gene discussed is DUSP1; the disease is neuroblastoma.